BSX vs HALO: fair value comparison
Boston Scientific Corporation and Halozyme Therapeutics, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BSX currently sits closer to the top of our discount ranking. HALO carries the stronger momentum grade.
| BSX | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $46.84 | $82.27 |
| 12-month range | $46.73–$106.66 | $63.96–$82.27 |
| Sector rank | #9 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | B | A |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: BSX fair value analysis · HALO fair value analysis